MX2021003654A - Metodo para seleccionar neoepitopes. - Google Patents

Metodo para seleccionar neoepitopes.

Info

Publication number
MX2021003654A
MX2021003654A MX2021003654A MX2021003654A MX2021003654A MX 2021003654 A MX2021003654 A MX 2021003654A MX 2021003654 A MX2021003654 A MX 2021003654A MX 2021003654 A MX2021003654 A MX 2021003654A MX 2021003654 A MX2021003654 A MX 2021003654A
Authority
MX
Mexico
Prior art keywords
selecting
neoepitopes
present
mhc
selecting neoepitopes
Prior art date
Application number
MX2021003654A
Other languages
English (en)
Spanish (es)
Inventor
Monika Sekelja
Agnete Brunsvik Fredriksen
Karoline Schjetne
Original Assignee
Nykode Therapeutics AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nykode Therapeutics AS filed Critical Nykode Therapeutics AS
Publication of MX2021003654A publication Critical patent/MX2021003654A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30Detection of binding sites or motifs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2021003654A 2018-09-27 2019-09-27 Metodo para seleccionar neoepitopes. MX2021003654A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18197172 2018-09-27
PCT/EP2019/076210 WO2020065023A1 (en) 2018-09-27 2019-09-27 Method for selecting neoepitopes

Publications (1)

Publication Number Publication Date
MX2021003654A true MX2021003654A (es) 2021-05-28

Family

ID=63794302

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003654A MX2021003654A (es) 2018-09-27 2019-09-27 Metodo para seleccionar neoepitopes.

Country Status (12)

Country Link
US (1) US12462898B2 (https=)
EP (1) EP3856957A1 (https=)
JP (1) JP7585195B2 (https=)
KR (1) KR102902460B1 (https=)
CN (1) CN112771214B (https=)
AU (1) AU2019346023B2 (https=)
BR (1) BR112021005702A8 (https=)
CA (1) CA3111903A1 (https=)
IL (1) IL281771B2 (https=)
MX (1) MX2021003654A (https=)
SG (1) SG11202101965QA (https=)
WO (1) WO2020065023A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020221783A1 (en) * 2019-04-29 2020-11-05 Vaccibody As Methods for pre-selection of neoepitopes
US20230197192A1 (en) * 2020-11-06 2023-06-22 Amazon Technologies, Inc. Selecting neoantigens for personalized cancer vaccine
GB202102606D0 (en) * 2021-02-24 2021-04-07 Univ Oxford Innovation Ltd Treatment of ovarian cancer minimal residual disease
IL305777A (en) 2021-03-26 2023-11-01 Nykode Therapeutics ASA Medical combination for cancer treatment
WO2022238420A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Co-expression of constructs and immunostimulatory compounds
WO2022238381A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunotherapy constructs for treatment of disease
WO2023244997A1 (en) * 2022-06-13 2023-12-21 The University Of North Carolina At Chapel Hill Compositions and methods for inducing anticancer immunity
EP4608436A1 (en) 2022-10-25 2025-09-03 Nykode Therapeutics ASA Constructs and their use
KR102857635B1 (ko) * 2022-11-08 2025-09-10 인바이츠지노믹스 주식회사 면역원성이 높은 유사체를 디자인하는 방법 및 이를 이용한 장치
WO2024100196A1 (en) 2022-11-09 2024-05-16 Nykode Therapeutics ASA Co-expression of constructs and polypeptides
WO2024216073A1 (en) * 2023-04-14 2024-10-17 The Trustees Of Columbia University In The City Of New York Engineered microbes comprising tumor neoantigen vectors for cancer immunotherapy
US20250232833A1 (en) * 2024-01-13 2025-07-17 Noergaard Anders Kaare Cyclin D1 Based Cancer Vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012029066A2 (pt) 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
HRP20211595T1 (hr) 2011-05-24 2022-01-21 BioNTech SE Individualizirana cjepiva protiv raka
WO2014082729A1 (en) 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
CN118750591A (zh) 2013-04-07 2024-10-11 博德研究所 用于个性化瘤形成疫苗的组合物和方法
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
JP6558699B2 (ja) 2013-10-01 2019-08-14 国立大学法人三重大学 抗原提示を促進するエピトープ間配列を含むt細胞誘導ワクチン
US11186640B2 (en) 2014-07-31 2021-11-30 The University Of Western Australia Method for the identification of immunotherapy-drug combinations using a network approach
EP3193892A4 (en) 2014-09-14 2018-09-12 Washington University Personalized cancer vaccines and methods therefor
US10317402B2 (en) 2014-12-03 2019-06-11 Verik Bio, Inc. Identification, selection and use of high curative potential T cell epitopes
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
CA2988388C (en) * 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
SG10201912485PA (en) * 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
EP3323070B1 (en) * 2015-07-14 2024-05-08 Personal Genome Diagnostics Inc. Neoantigen analysis
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
WO2018136664A1 (en) * 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules

Also Published As

Publication number Publication date
JP2022502416A (ja) 2022-01-11
BR112021005702A2 (pt) 2021-06-22
IL281771B1 (en) 2025-04-01
AU2019346023A1 (en) 2021-03-25
BR112021005702A8 (pt) 2022-11-08
US12462898B2 (en) 2025-11-04
WO2020065023A1 (en) 2020-04-02
US20210388438A1 (en) 2021-12-16
JP7585195B2 (ja) 2024-11-18
CA3111903A1 (en) 2020-04-02
CN112771214A (zh) 2021-05-07
KR102902460B1 (ko) 2025-12-19
EP3856957A1 (en) 2021-08-04
IL281771B2 (en) 2025-08-01
CN112771214B (zh) 2025-06-13
KR20210065171A (ko) 2021-06-03
AU2019346023B2 (en) 2024-12-12
SG11202101965QA (en) 2021-04-29
IL281771A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
MX2021003654A (es) Metodo para seleccionar neoepitopes.
ECSP20078226A (es) Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
SV2017005355A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
CL2018000422A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
MX391279B (es) Anticuerpos biespecíficos contra cd3 y cd20.
ECSP17045736A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
PY1800237A (es) Aislados de bacillus y usos de los mismos
UY37564A (es) Aislados de lysinibacillus y usos de los mismos
MX370018B (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
CO2017002719A2 (es) Anticuerpos anti-glucagón
PE20191812A1 (es) Compuestos y metodos para la reduccion celular especifica de tumor
CL2017002728A1 (es) Método para el tratamiento de cáncer
AR088171A1 (es) Anticuerpos anti-erbb3 y usos de los mismos
MX373280B (es) Anticuerpos anti-egfrviii y usos de los mismos.
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
MX2016013239A (es) Tratamiento de cancer utilizando receptor quimerico de antigeno anti-cd19.
PE20171135A1 (es) Metodos para seleccionar una linea de celulas t y donador de la misma para terapia celular adoptiva
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
AR103726A1 (es) Cristales de anticuerpos monoclonales anti-pd-1 humanos
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
AR095348A1 (es) Medios de cultivo celular y métodos de producción de anticuerpos
MX378368B (es) Receptores de antigeno y usos de los mismos.
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
MX2020012649A (es) Neoantígenos especificos de tumor y métodos de uso de estos.